Search Results - "Tiwari, Anand D."

Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia by Guan, Yihong, Hasipek, Metis, Jiang, Dongxu, Tiwari, Anand D, Grabowski, Dale R, Pagliuca, Simona, Kongkiatkamon, Sunisa, Patel, Bhumika, Singh, Salendra, Parker, Yvonne, LaFramboise, Thomas, Lindner, Daniel, Sekeres, Mikkael A, Mian, Omar Y, Saunthararajah, Yogen, Maciejewski, Jaroslaw P, Jha, Babal K

“…Eltrombopag, an FDA-approved non-peptidyl thrombopoietin receptor agonist, is clinically used for the treatment of aplastic anemia, a disease characterized by…”
Get full text

Synthesis, antibacterial properties and 2D-QSAR studies of quinolone-triazole conjugates by Faidallah, Hassan M., Girgis, Adel S., Tiwari, Anand D., Honkanadavar, Hitesh H., Thomas, Sean J., Samir, Ahmed, Kalmouch, Atef, Alamry, Khalid A., Khan, Khalid A., Ibrahim, Tarek S., AL-Mahmoudy, Amany M.M., Asiri, Abdullah M., Panda, Siva S.

“…A set of 1,2,3-triazole incorporated quinolone antibiotic conjugates 10–15, 17–19 were synthesized via microwave assisted click chemistry technique. Some of…”
Get full text

Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple Myeloma by Hasipek, Metis, Grabowski, Dale, Guan, Yihong, Alugubelli, Raghunandan Reddy, Tiwari, Anand D., Gu, Xiaorong, DeAvila, Gabriel A., Silva, Ariosto S., Meads, Mark B., Parker, Yvonne, Lindner, Daniel J., Saunthararajah, Yogen, Shain, Kenneth H., Maciejewski, Jaroslaw P., Reu, Frederic J., Phillips, James G., Jha, Babal K.

“…Multiple myeloma is a genetically complex hematologic neoplasia in which malignant plasma cells constantly operate at the maximum limit of their unfolded…”
Get full text

TET-dioxygenase deficiency in oncogenesis and its targeting for tumor-selective therapeutics by Guan, Yihong, Hasipek, Metis, Tiwari, Anand D., Maciejewski, Jaroslaw P., Jha, Babal K.

“…TET2 is one of the most frequently mutated genes in myeloid neoplasms. TET2 loss-of-function perturbs myeloid differentiation and causes clonal expansion…”
Get full text

A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms by Guan, Yihong, Tiwari, Anand D, Phillips, James G, Hasipek, Metis, Grabowski, Dale R, Pagliuca, Simona, Gopal, Priyanka, Kerr, Cassandra M, Adema, Vera, Radivoyevitch, Tomas, Parker, Yvonne, Lindner, Daniel J, Meggendorfer, Manja, Abazeed, Mohamed, Sekeres, Mikkeal A, Mian, Omar Y, Haferlach, Torsten, Maciejewski, Jaroslaw P, Jha, Babal K

“…is frequently mutated in myeloid neoplasms. Genetic TET2 deficiency leads to skewed myeloid differentiation and clonal expansion, but minimal residual TET…”
Get full text

SAR insights into TET2 catalytic domain inhibition: Synthesis of 2-Hydroxy-4-Methylene-pentanedicarboxylates by Tiwari, Anand D., Guan, Yihong, Grabowski, Dale R., Maciejewski, Jaroslaw P., Jha, Babal K., Phillips, James G.

“…[Display omitted] The TET (Ten-Eleven Translocation) dioxygenase enzyme family comprising 3 members, TET1-3, play key roles in DNA demethylation. These…”
Get full text

New benzotriazole-based reagents for the phosphonylation of various N-, O-, and S-nucleophiles by Panmand, Deepak S., Tiwari, Anand D., Panda, Siva S., Monbaliu, Jean-Christophe M., Beagle, Lucas K., Asiri, Abdullah M., Stevens, Christian V., Steel, Peter J., Hall, C. Dennis, Katritzky, Alan R.

“…•New phosphonylation reagents were developed.•Benzotriazole surrogates showing higher stabilities than the chlorophosphates.•The…”
Get full text

A First-in-Class Inhibitor of ISWI-Mediated (ATP-Dependent) Transcription Repression Releases Terminal-Differentiation in AML Cells While Sparing Normal Hematopoiesis by Kishtagari, Ashwin, Ng, Kwok Peng, Jarman, Charlotte, Tiwari, Anand D., Phillips, James G, Schuerger, Caroline, Jha, Babal K., Saunthararajah, Yogenthiran

“…Acute myeloid leukemia (AML) cells express the PU.1/RUNX1/CEBPA master transcription factor circuit at levels similar to or exceeding that in normal…”
Get full text

Stabilisation of silver and copper nanoparticles in a chemically modified chitosan matrix by Tiwari, Anand D., Mishra, Ajay K., Mishra, Shivani B., Kuvarega, Alex T., Mamba, Bhekie B.

“…► Stabilisation of Ag (20nm) and Cu (50nm) nanoparticles. ► Better optical properties for silver nanoparticles as surface plasmon band (407nm). ► Optical…”
Get full text

Microwave assisted synthesis and QSAR study of novel NSAID acetaminophen conjugates with amino acid linkers by Tiwari, Anand D, Panda, Siva S, Girgis, Adel S, Sahu, Sandhyamayee, George, Riham F, Srour, Aladdin M, La Starza, Brian, Asiri, Abdullah M, Hall, C Dennis, Katritzky, Alan R

“…Novel, non-steroidal anti-inflammatory drug (NSAID), acetaminophen conjugates 6a–l with amino acid linkers were synthesized utilizing benzotriazole chemistry…”
Get more information

Green synthesis and stabilization of gold nanoparticles in chemically modified chitosan matrices by Tiwari, Anand D., Mishra, Ajay K., Mishra, Shivani B., Arotiba, Omotayo A., Mamba, Bhekie B.

“…Chitosan-N-2-methylhydroxypyridine-6-methylcorboxylate (Ch-PDC) and chitosan-N-2-methylhydroxypyridine-6-methylhydroxy thiocarbohydrazide (Ch-PDC-Th) were…”
Get full text

Ligations of O-acyl threonine units to give native peptides via 5-, 8-, 9- and 10-membered cyclic transition states by Panda, Siva S., Liaqat, Sumaira, Tiwari, Anand D., Marwani, Hadi M., Faidallah, Hassan M., Rauf, Abdul, Hall, C. Dennis, Katritzky, the late Alan R.

Get full text

Therapeutic Targeting of TET-Dioxygenase Deficiency in Myeloid Malignancies by Guan, Yihong, Tiwari, Anand D., Hasipek, Metis, Grabowski, Dale, Lindner, Daniel, Phillips, James G, Mian, Omar, Xu, Mingjiang, Maciejewski, Jaroslaw P., Jha, Babal K.

“…Background: TET-dioxygenases (TET1, TET2, and TET3) are key epigenetic regulators, which require molecular oxygen, αKG, and Fe 2+ to progressively oxidize…”
Get full text

Heightened Endoplasmic-Reticulum Stress Is a Targetable Vulnerability of Malignant Plasma Cells in Multiple Myeloma by Dima, Danai, Hasipek, Metis, Singh, Divya Jyoti, Jiang, Dongxu, Tiwari, Anand D., Grabowski, Dale, Parker, Yvonne, Lindner, Daniel J., Zhao, Jianjun, Shain, Kenneth H., Khouri, Jack, Maciejewski, Jaroslaw P., Jha, Babal K.

Get full text

A Novel Therapeutic Strategy for Preferential Elimination of Multiple Myeloma Cells By Targeting Protein Disulfide Isomerase by Hasipek, Metis, Grabowski, Dale, Guan, Yihong, Tiwari, Anand D., Gu, Xiaorong, Valent, Jason, Maciejewski, Jaroslaw, Reu, Frederic Joel, Phillips, James G, Jha, Babal K.

“…Multiple myeloma (MM) is a genetically complex hematological disease which is characterized by clonal proliferation of plasma cells in the bone marrow and…”
Get full text

Inhibition of Critical DNA Dioxygenase Activity in IDH1/2 Mutant Myeloid Neoplasms by Pagliuca, Simona, Guan, Yihong, Tiwari, Anand D., Grabowski, Dale, Gurnari, Carmelo, Kerr, Cassandra M, Kongkiatkamon, Sunisa, Hasipek, Metis, Terkawi, Laila, Zawit, Misam, Awada, Hassan, Visconte, Valeria, Saunthararajah, Yogenthiran, Phillips, James G, Maciejewski, Jaroslaw P., Jha, Babal K.

“…Neomorphic mutations in IDH1/2 producing R-2-Hydroxyglutrate (R-2HG), are common in myeloid malignancies and in various solid cancers. A diffuse…”
Get full text

TET2 Inhibitory Effects of Eltrombopag Contribute Its Hematopoietic Activity by Guan, Yihong, Hasipek, Metis, Patel, Bhumika J., Grabowski, Dale, Tiwari, Anand D., Kongkiatkamon, Sunisa, Kerr, Cassandra M, Nazha, Aziz, Saunthararajah, Yogenthiran, Sekeres, Mikkael A., Maciejewski, Jaroslaw P., Jha, Babal K.

“…Severe aplastic anemia (sAA) is bone marrow (BM) failure syndrome characterized by immune mediated BM hypoplasia and pancytopenia usually treated with…”
Get full text

Targeting NAD+ Modulating Enzymes to Improve HSC Function in Aging and Bone Marrow Failure by Maciejewski, Phillip J, Guan, Yihong, Hasipek, Metis, Tiwari, Anand D., Grabowski, Dale, Phillips, James G, Saunthararajah, Yogenthiran, Maciejewski, Jaroslaw P., Jha, Babal K.

“…Human hematopoietic system produces various types of differentiated and short-lived cells with specialized functions, which require continuous replenishment…”
Get full text

TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia by Guan, Yihong, Tiwari, Anand D., Phillips, James G, Hasipek, Metis, Grabowski, Dale, Kerr, Cassandra M, Adema, Vera, Nagata, Yasunobu, Visconte, Valeria, Radivoyevitch, Tomas, Lindner, Daniel, Meggendorfer, Manja, Abazeed, Mohamed, Sekeres, Mikkael A., Haferlach, Torsten, Maciejewski, Jaroslaw P., Jha, Babal K.

“…TET2 is one of the most commonly mutated genes in myeloid neoplasia. Somatic TET2 mutations (TET2MT) cause complete or partial loss of enzymatic activity. TET2…”
Get full text

Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases by Guan, Yihong, Tiwari, Anand D., Hasipek, Metis, Grabowski, Dale, Parker, Yvonne, Hirsch, Cassandra M., Graham, Amy C, Nagata, Yasunobu, Przychodzen, Bartlomiej P., Nazha, Aziz, Lindner, Daniel, Radivoyevitch, Tomas, Phillips, James G, Maciejewski, Jaroslaw P., Jha, Babal K.

“…Discovery of many somatic lesions in leukemia enables development of targeted therapies. TET2 is one of the most frequently mutated genes in MDS/related…”
Get full text